Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: Advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors

Current Cancer Drug Targets

Volumn 7, Issue 7, 2007, Pages 666-673

  Ahmed, Syed M ^a   Cohen, Ezra E W ^a,b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b University of Chicago   (United States)

Author keywords

Chemotherapy; Epidermal growth factor receptor; Head and neck cancer; Metastases; Protein kinase inhibitors; Quinazolines

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AMINOTRANSFERASE; BEVACIZUMAB; BLEOMYCIN; CARBOPLATIN; CELECOXIB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; GEFITINIB; GEMCITABINE; HYDROXYUREA; IFOSFAMIDE; IMATINIB; IXABEPILONE; LAPATINIB; MESNA; METHOTREXATE; NAVELBINE; PACLITAXEL; PELITINIB; TAXANE DERIVATIVE; UNINDEXED DRUG; VANDETANIB; VINCRISTINE;

ADVANCED CANCER; AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG TARGETING; EARLY CANCER; FATIGUE; FEBRILE NEUTROPENIA; GENE EXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; HYPERTENSION; METASTASIS; MULTIPLE CYCLE TREATMENT; PREVALENCE; PROGNOSIS; PROTEIN DOMAIN; RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM RECURRENCE, LOCAL; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 35948983764     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800907782418293     Document Type: Review

References (99)

1. Parkin, D. M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55, 74-108.
2. Jemal, A.; Murray, T.; Ward, E.; Samuels, A.; Tiwari, R. C.; Ghafoor, A.; Feuer, E. J.; Thun, M. J. Cancer statistics, 2005. CA Cancer J. Clin. 2005, 55, 10-30.
3. Cohen, E. E.; Lingen, M. W.; Vokes, E. E. The expanding role of systemic therapy in head and neck cancer. J. Clin. Oncol. 2004, 22, 1743-1752.
4. Leon, X.; Hitt, R.; Constenla, M.; Rocca, A.; Stupp, R.; Kovacs, A. F.; Amellal, N.; Bessa, E. H.; Bourhis, J. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin. Oncol. (R. Coll. Radiol.) 2005, 17, 418-424.
5. Wittes, R.; Heller, K.; Randolph, V.; Howard, J.; Vallejo, A.; Farr, H.; Harrold, C.; Gerold, F.; Shah, J.; Spiro, R.; Strong, E. cis- Dichlorodiammineplatinum(II)-based chemotherapy as initial treatment of advanced head and neck cancer. Cancer Treat. Rep. 1979, 63, 1533-1538.
6. Pinto, H. A.; Jacobs, C. Chemotherapy for recurrent and metastatic head and neck cancer. Hematol. Oncol. Clin. North Am. 1991, 5, 667-686.
7. Jacobs, C.; Lyman, G.; Velez-Garcia, E.; Sridhar, K. S.; Knight, W.; Hochster, H.; Goodnough, L. T.; Mortimer, J. E.; Einhorn, L. H.; Schacter, L. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J. Clin. Oncol. 1992, 10, 257-263.
8. Forastiere, A. A.; Metch, B.; Schuller, D. E.; Ensley, J. F.; Hutchins, L. F.; Triozzi, P.; Kish, J. A.; McClure, S.; VonFeldt, E.; Williamson, S. K. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J. Clin. Oncol. 1992, 10, 45-51.
9. Clavel, M.; Vermorken, J. B.; Cognetti, F.; Cappelaere, P.; de Mulder, P. H.; Schornagel, J. H.; Tueni, E. A.; Verweij, J.; Wildiers, J.; Clerico, M.; Dalesio, O.; Kirkpatrick, A.; Snow, G. B. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann. Oncol. 1994, 5, 521-526.
10. Forastiere, A. A.; Shank, D.; Neuberg, D.; Taylor, S. G. 4th.; DeConti, R. C.; Adams, G. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 1998, 82, 2270-2274.
11. Catimel, G.; Verweij, J.; Mattijssen, V.; Hanauske, A.; Piccart, M.; Wanders, J.; Franklin, H.; Le Bail, N.; Clavel, M.; Kaye, S. B. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann. Oncol. 1994, 5, 533-537.
12. Dreyfuss, A. I.; Clark, J. R.; Norris, C. M.; Rossi, R. M.; Lucarini, J. W.; Busse, P. M.; Poulin, M. D.; Thornhill, L.; Costello, R.; Posner, M. R. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J. Clin. Oncol. 1996, 14, 1672-1678.
13. Pivot, X.; Cals, L.; Cupissol, D.; Guardiola, E.; Tchiknavorian, X.; Guerrier, P.; Merad, L.; Wendling, J. L.; Barnouin, L.; Savary, J.; Thyss, A.; Schneider, M. Phase II trial of a paclitaxel-carboplatin combination in recurrent squamous cell carcinoma of the head and neck. Oncology 2001, 60, 66-71.
14. Caponigro, F.; Massa, E.; Manzione, L.; Rosati, G.; Biglietto, M.; De Lucia, L.; Sguotti, C.; Sganga, P.; Avallone, A.; Comella, P.; Mantovani, G.; Comella, G. Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG). Ann. Oncol. 2001, 12, 199-202.
15. Glisson, B. S.; Murphy, B. A.; Frenette, G.; Khuri, F. R.; Forastiere, A. A. Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2002, 20, 1593-1599.
16. Specht, L.; Larsen, S. K.; Hansen, H. S. Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck. Ann. Oncol. 2000, 11, 845-849.
17. Gibson, M. K.; Li, Y.; Murphy, B.; Hussain, M. H.; DeConti, R. C.; Ensley, J.; Forastiere, A. A. Eastern Cooperative Oncology Group. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 2005, 23, 3562-3567.
18. Hitt, R.; Castellano, D.; Hidalgo, M.; Garcia-Carbonero, R.; Pena, M.; Brandariz, A.; Millan, J. M.; Alvarez-Vincent, J. J.; Cortes-Funes, H. Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck. Ann. Oncol. 1998, 9, 1347-1349.
19. Raguse, J. D.; Gath, H. J.; Bier, J.; Riess, H.; Oettle, H. Gemcitabine in the treatment of advanced head and neck cancer. Clin. Oncol. (R. Coll. Radiol.) 2005, 17, 425-429.
20. Degardin, M.; Oliveira, J.; Geoffrois, L.; Rolland, F.; Armand, J. P.; Bastit, P.; Chauvergne, J.; Fargeot, P.; van Glabbeke, M.; Lentz, M. A.; Tresca, P.; Boudillet, J.; Fumoleau, P.; Cappelaere, P. An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann. Oncol. 1998, 9, 1103-1107.
21. Espinosa, E.; Zamora, P.; Milla, A.; Morales, S.; Molina, R.; Mira, M.; Gonzalez-Baron, M.; Oncopaz Cooperative Group. A phase II trial of cisplatin and vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck 2002, 24, 1054-1059.
22. Airoldi, M.; Cattel, L.; Marchionatti, S.; Recalenda, V.; Pedani, F.; Tagini, V.; Bumma, C.; Beatrice, F.; Succo, G.; Maria-Gabriele, A. Docetaxel and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. Am. J. Clin. Oncol. 2003, 26, 378-381.
23. Gedlicka, C.; Kornfehl, J.; Turhani, D.; Burian, M.; Formanek, M. Salvage therapy with oral etoposide in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Cancer Invest. 2006, 24, 242-245.
24. Kodaira, T.; Fuwa, N.; Tachibana, H.; Hidano, S. Phase I study of S-1 and nedaplatin for patients with recurrence of head and neck cancer. Anticancer Res. 2006, 26, 2265-2268.
25. Shin, D. M.; Glisson, B. S.; Khuri, F. R.; Hong, W. K.; Lippman, S. M. Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Semin. Oncol. 1998, 25(2 Suppl. 4), 40-44.
26. Shin, D. M.; Khuri, F. R.; Glisson, B. S.; Ginsberg, L.; Papadimitrakopoulou, V. M.; Clayman, G.; Lee J. J.; Ang, K. K.; Lippman, S. M.; Hong W. K. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer 2001, 91, 1316-1323.
27. Janinis, J.; Papadakou, M.; Xidakis, E.; Boukis, H.; Poulis, A.; Panagos, G.; Lefantzis, D. Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study. Am. J. Clin. Oncol. 2000, 23, 128-131.
28. Schena, M.; Barone, C.; Birocco, N.; Dongiovanni, D.; Numico, G.; Colantonio, I.; Bertetto, O. Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study. Cancer Chemother. Pharmacol. 2005, 55, 271-276.
29. Hitt, R.; Lopez-Pousa, A.; Martinez-Trufero, J.; Escrig, V.; Carles, J.; Rizo, A.; Isla, D.; Vega, M. E.; Marti, J. L.; Lobo, F.; Pastor, P.; Valenti, V.; Belon, J.; Sanchez, M. A.; Chaib, C.; Pallares, C.; Anton, A.; Cervantes, A.; Paz-Ares, L.; Cortes-Funes, H. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J. Clin. Oncol. 2005, 23, 8636-8645.
30. Haraf, D. J.; Rosen, F. R.; Stenson, K.; Argiris, A.; Mittal, B. B.; Witt, M. E.; Brockstein, B. E.; List, M. A.; Portugal, L.; Pelzer, H.; Weichselbaum, R. R.; Vokes, E. E. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin. Cancer Res. 2003, 9, 5936-5943.
31. Vokes, E. E.; Stenson, K.; Rosen, F. R.; Kies, M. S.; Rademaker, A. W.; Witt, M. E.; Brockstein, B. E.; List, M. A.; Fung, B. B.; Portugal, L.; Mittal, B. B.; Pelzer, H.; Weichselbaum, R. R.; Haraf, D. J. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J. Clin. Oncol. 2003, 21, 320-326.
32. Druker, B. J.; Talpaz, M.; Resta, D. J.; Peng, B.; Buchdunger, E.; Ford, J. M.; Lydon, N. B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S.; Sawyers, C. L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 2001, 344, 1031-1037.
33. Verweij, J.; van Oosterom, A.; Blay, J. Y.; Judson, I.; Rodenhuis, S.; van der Graaf, W.; Radford, J.; Le Cesne, A.; Hogendoorn, P. C.; di Paola, E. D.; Brown, M.; Nielsen, O. S. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur. J. Cancer 2003, 39, 2006-2011.
34. Rusch, V.; Klimstra, D.; Venkatraman, E.; Pisters, P. W.; Langenfeld, J.; Dmitrovsky, E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin. Cancer Res. 1997, 3, 515-522.
35. Rubin Grandis, J.; Melhem, M. F.; Gooding, W. E.; Day, R.; Holst, V. A.; Wagener, M. M.; Drenning, S. D.; Tweardy, D. J. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl. Cancer Inst. 1998, 90, 824-832.
36. Putti, T. C.; To, K. F.; Hsu, H. C.; Chan, A. T.; Lai, G. M.; Tse, G.; Lee, Y. S.; Whang-Peng, J.; Millward, M.; Lin, L.; Lin, X.; Lee, C. S. Expression of epidermal growth factor receptor in head and neck cancers correlates with clinical progression: a multicentre immunohistochemical study in the Asia-Pacific region. Histopathology 2002, 41, 144-151.
37. Laskin, J. J.; Sandler, A. B. Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat. Rev. 2004, 30, 1-17.
38. Moriki, T.; Maruyama, H.; Maruyama, I. N. Activation of preformed EGF receptor dimers by ligand-induced rotation of the transmembrane domain. J. Mol. Biol. 2001, 311, 1011-1026.
39. Sweeney, C.; Carraway, K. L., 3rd. Ligand discrimination by ErbB receptors: differential signaling through differential phosphorylation site usage. Oncogene 2000, 19, 5568-5573.
40. Phillips, R. J.; Mestas, J.; Gharaee-Kermani, M.; Burdick, M. D.; Sica, A.; Belperio, J. A.; Keane, M. P.; Strieter, R. M. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/ mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J. Biol. Chem. 2005, 280, 22473-22481.
41. Yang, C.; Liu, Y.; Lemmon, M. A.; Kazanietz, M. G. Essential role for Rac in heregulin beta-1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4. Mol. Cell. Biol. 2006, 26, 831-842.
42. Nakamura, N.; Chin, H.; Miyasaka, N.; Miura, O. An epidermal growth factor receptor/Jak2 tyrosine kinase domain chimera induces tyrosine phosphorylation of Stat5 and transduces a growth signal in hematopoietic cells. J. Biol. Chem. 1996, 271, 19483-19488.
43. Williams, R.; Sanghera, J.; Wu, F.; Carbonaro-Hall, D.; Campbell, D. L.; Warburton, D.; Pelech, S.; Hall, F. Identification of a human epidermal growth factor receptor-associated protein kinase as a new member of the mitogen-activated protein kinase/extracellular signal-regulated protein kinase family. J. Biol. Chem. 1993, 268, 18213-18217.
44. Fukuoka, M.; Yano, S.; Giaccone, G.; Tamura, T.; Nakagawa, K.; Douillard, J. Y.; Nishiwaki, Y.; Vansteenkiste, J.; Kudoh, S.; Rischin, D.; Eek, R.; Horai, T.; Noda, K.; Takata, I.; Smit, E.; Averbuch, S.; Macleod, A.; Feyereislova, A.; Dong, R. P.; Baselga, J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J. Clin. Oncol. 2003, 21, 2237-2246.
45. Shepherd, F. A.; Rodrigues-Pereira, J.; Ciuleanu, T.; Tan, E. H.; Hirsh, V.; Thongprasert, S.; Campos, D.; Maoleekoonpiroj, S.; Smylie, M.; Martins, R.; van Kooten, M.; Dediu, M.; Findlay, B.; Tu, D.; Johnston, D.; Bezjak, A.; Clark, G.; Santabarbara, P.; Seymour, L. National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 2005, 353, 123-132.
46. Ciardiello, F.; Tortora, G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. 2001, 7, 2958-2970.
47. Nakamura, Y.; Oka, M.; Soda, H.; Shiozawa, K.; Yoshikawa, M.; Itoh, A.; Ikegami, Y.; Tsurutani, J.; Nakatomi, K.; Kitazaki, T.; Doi, S.; Yoshida, H.; Kohno, S. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res. 2005, 65, 1541-1546.
48. Brehmer, D.; Greff, Z.; Godl, K.; Blencke, S.; Kurtenbach, A.; Weber, M.; Muller, S.; Klebl, B.; Cotton, M.; Keri, G.; Wissing, J.; Daub, H. Cellular targets of gefitinib. Cancer Res. 2005, 65, 379-382.
49. Erlichman, C.; Hidalgo, M.; Boni, J. P.; Martins, P.; Quinn, S. E.; Zacharchuk, C.; Amorusi, P.; Adjei, A. A.; Rowinsky, E. K. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J. Clin. Oncol. 2006, 24, 2252-2260.
50. Bruns, C. J.; Solorzano, C. C.; Harbison, M. T.; Ozawa, S.; Tsan, R.; Fan, D.; Abbruzzese, J.; Traxler, P.; Buchdunger, E.; Radinsky, R.; Fidler, I. J. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 2000, 60, 2926-2935.
51. Holsinger, F. C.; Doan, D. D.; Jasser, S. A.; Swan, E. A.; Greenberg, J. S.; Schiff, B. A.; Bekele, B. N.; Younes, M. N.; Bucana, C. D.; Fidler, I. J.; Myers, J. N. Epidermal growth factor receptor blockade potentiates apoptosis mediated by paclitaxel and leads to prolonged survival in a murine model of oral cancer. Clin. Cancer Res. 2003, 9, 3183-3189.
52. Myers, J. N.; Holsinger, F. C.; Bekele, B. N.; Li, E.; Jasser, S. A.; Killion, J. J.; Fidler, I. J. Targeted molecular therapy for oral cancer with epidermal growth factor receptor blockade: a preliminary report. Arch. Otolaryngol. Head Neck Surg. 2002, 128, 875-879.
53. Herbst, R. S.; Prager, D.; Hermann, R.; Fehrenbacher, L.; Johnson, B. E.; Sandler, A.; Kris, M. G.; Tran, H. T.; Klein, P.; Li, X.; Ramies, D.; Johnson, D. H.; Miller, V. A; TRIBUTE Investigator Group. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 2005, 23, 5892-5899.
54. Herbst, R. S.; Giaccone, G.; Schiller, J. H.; Natale, R. B.; Miller, V.; Manegold, C.; Scagliotti, G.; Rosell, R.; Oliff, I.; Reeves, J. A.; Wolf, M. K.; Krebs, A. D.; Averbuch, S. D.; Ochs, J. S.; Grous, J.; Fandi, A.; Johnson, D. H. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J. Clin. Oncol. 2004, 22, 785-794.
55. Moore, M. J.; Goldstein, D.; Hamm, J.; Figer, A.; Hecht, J. R.; Gallinger, S.; Au, H. J.; Murawa, P.; Walde, D.; Wolff, R. A.; Campos, D.; Lim, R.; Ding, K.; Clark, G.; Voskoglou-Nomikos, T.; Ptasynski, M.; Parulekar, W. National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007, 25, 1960-1966.
56. Cohen, E. E.; Rosen, F.; Stadler, W. M.; Recant, W.; Stenson, K.; Huo, D.; Vokes, E. E. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2003, 21, 1980-1987.
57. Kirby, A. M.; A'Hern, R. P.; D'Ambrosio, C.; Tanay, M.; Syrigos, K. N.; Rogers, S. J.; Box, C.; Eccles, S. A.; Nutting, C. M.; Harrington, K. J. Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br. J. Cancer 2006, 94, 631-636.
58. Cohen, E. E.; Kane, M. A.; List, M. A.; Brockstein, B. E.; Mehrotra, B.; Huo, D.; Mauer, A. M.; Pierce, C.; Dekker, A.; Vokes, E. E. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin. Cancer Res. 2005, 11, 8418-8424.
59. Wirth, L. J.; Haddad, R. I.; Lindeman, N. I.; Zhao, X.; Lee, J. C.; Joshi, V. A.; Norris, C. M. Jr.; Posner, M. R. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2005, 23, 6976-6981.
60. Chinnaiyan, P.; Huang, S.; Vallabhaneni, G.; Armstrong, E.; Varambally, S.; Tomlins, S. A.; Chinnaiyan, A. M.; Harari, P. M. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res. 2005, 65, 3328-3335.
61. Hidalgo, M.; Siu, L. L.; Nemunaitis, J.; Rizzo, J.; Hammond, L. A.; Takimoto, C.; Eckhardt, S. G.; Tolcher, A.; Britten, C. D.; Denis, L.; Ferrante, K.; Von Hoff, D. D.; Silberman, S.; Rowinsky, E. K. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. 2001, 19, 3267-3279.
62. Soulieres, D.; Senzer, N. N.; Vokes, E. E.; Hidalgo, M.; Agarwala, S. S.; Siu, L. L. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J. Clin. Oncol. 2004, 22, 77-85.
63. Viloria-Petit, A.; Crombet, T.; Jothy, S.; Hicklin, D.; Bohlen, P.; Schlaeppi, J. M.; Rak, J.; Kerbel, R. S. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 2001, 61, 5090-5101.
64. Pinkas-Kramarski, R.; Soussan, L.; Waterman, H.; Levkowitz, G.; Alroy, I.; Klapper, L.; Lavi, S.; Seger, R.; Ratzkin, B. J.; Sela, M.; Yarden, Y. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 1996, 15, 2452-2467.
65. Karunagaran, D.; Tzahar, E.; Beerli, R. R.; Chen, X.; Graus-Porta, D.; Ratzkin, B. J.; Seger, R.; Hynes, N. E.; Yarden, Y. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J. 1996, 15, 254-264.
66. Hoekstra, R.; Dumez, H.; Eskens, F. A.; van der Gaast, A.; Planting, A. S.; de Heus, G.; Sizer, K. C.; Ravera, C.; Vaidyanathan, S.; Bucana, C.; Fidler, I. J.; van Oosterom, A. T.; Verweij, J. Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Clin. Cancer Res. 2005, 11, 6908-6915.
67. Ciardiello, F.; Caputo, R.; Damiano, V.; Caputo, R.; Troiani, T.; Vitagliano, D.; Carlomagno, F.; Veneziani, B. M.; Fontanini, G.; Bianco, A. R.; Tortora, G. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin. Cancer Res. 2003, 9, 1546-1556.
68. Holden, S. N.; Eckhardt, S. G.; Basser, R.; de Boer, R.; Rischin, D.; Green, M.; Rosenthal, M. A.; Wheeler, C.; Barge, A.; Hurwitz, H. I. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann. Oncol. 2005, 16, 1391-1397.
69. Lee, D. Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer. Clin. Lung Cancer 2005, 7, 89-91.
70. Traxler, P.; Allegrini, P. R.; Brandt, R.; Brueggen, J.; Cozens, R.; Fabbro, D.; Grosios, K.; Lane, H. A.; McSheehy, P.; Mestan, J.; Meyer, T.; Tang, C.; Wartmann, M.; Wood, J.; Caravatti, G. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 2004, 64, 4931-4941.
71. Yigitbasi, O. G.; Younes, M. N.; Doan, D.; Jasser, S. A.; Schiff, B. A.; Bucana, C. D.; Bekele, B. N.; Fidler, I. J.; Myers, J. N. Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade. Cancer Res. 2004, 64, 7977-7984.
72. Tsao, M. S.; Sakurada, A.; Cutz, J. C.; Zhu, C. Q.; Kamel-Reid, S.; Squire, J.; Lorimer, I.; Zhang, T.; Liu, N.; Daneshmand, M.; Marrano, P.; da Cunha-Santos, G.; Lagarde, A.; Richardson, F.; Seymour, L.; Whitehead, M.; Ding, K.; Pater, J.; Shepherd, F. A. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N. Engl. J. Med. 2005, 353, 133-144.
73. Janmaat, M. L.; Gallegos-Ruiz, M. I.; Rodriguez, J. A.; Meijer, G. A.; Vervenne, W. L.; Richel, D. J.; Van Groeningen, C.; Giaccone, G. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J. Clin. Oncol. 2006, 24, 1612-1619.
74. Perez-Soler, R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology (Williston Park) 2003, 17, 23-28.
75. Lynch, T. J.; Bell, D. W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R. A.; Brannigan, B. W.; Harris, P. L.; Haserlat, S. M.; Supko, J. G.; Haluska, F. G.; Louis, D. N.; Christiani, D. C.; Settleman, J.; Haber, D. A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350, 2129-2139.
76. Paez, J. G.; Janne, P. A.; Lee, J. C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F. J.; Lindeman, N.; Boggon, T. J.; Naoki, K.; Sasaki, H.; Fujii, Y.; Eck, M. J.; Sellers, W. R.; Johnson, B. E.; Meyerson, M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497-1500.
77. Pao, W.; Miller, V.; Zakowski, M.; Doherty, J.; Politi, K.; Sarkaria, I.; Singh, B.; Heelan, R.; Rusch, V.; Fulton, L.; Mardis, E.; Kupfer, D.; Wilson, R.; Kris, M.; Varmus, H. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 2004, 101, 13306-13311.
78. Pao, W.; Miller, V. A.; Politi, K. A.; Riely, G. J.; Somwar, R.; Zakowski, M. F.; Kris, M. G.; Varmus, H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS. Med. 2005, 2, e73.
79. Choong, N. W.; Dietrich, S.; Seiwert, T. Y.; Tretiakova, M. S.; Nallasura, V.; Davies, G. C.; Lipkowitz, S.; Husain, A. N.; Salgia, R.; Ma, P. C. Gefitinib response of erlotinib-refractory lung cancer involving meninges - role of EGFR mutation. Nat. Clin. Pract. Oncol. 2006, 3, 50-57.
80. Loeffler-Ragg, J.; Witsch-Baumgartner, M.; Tzankov, A.; Hilbe, W.; Schwentner, I.; Sprinzl, G. M.; Utermann, G.; Zwierzina, H. Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur. J. Cancer 2006, 42, 109-111.
81. Lee, J. W.; Soung, Y. H.; Kim, S. Y.; Nam, H. K.; Park, W. S.; Nam, S. W.; Kim, M. S.; Sun, D. I.; Lee, Y. S.; Jang, J. J.; Lee, J. Y.; Yoo, N. J.; Lee, S. H. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin. Cancer Res. 2005, 11, 2879-2882.
82. Cohen, E. E.; Lingen, M. W.; Martin, L. E.; Harris P. L.; Brannigan, B. W.; Haserlat, S. M.; Okimoto, R. A.; Sgroi, D. C.; Dahiya, S.; Muir, B.; Clark, J. R.; Rocco, J. W.; Vokes, E. E.; Haber, D. A.; Bell, D. W. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin. Cancer Res. 2005, 11, 8105-8108.
83. Bell, D. W.; Lynch, T. J.; Haserlat, S. M.; Harris, P. L.; Okimoto, R. A.; Brannigan, B. W.; Sgroi, D. C.; Muir, B.; Riemenschneider, M. J.; Iacona, R. B.; Krebs, A. D.; Johnson, D. H.; Giaccone, G.; Herbst, R. S.; Manegold, C.; Fukuoka, M.; Kris, M. G.; Baselga, J.; Ochs, J. S.; Haber, D. A. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J. Clin. Oncol. 2005, 23, 8081-8092.
84. Takano, T.; Ohe, Y.; Sakamoto, H.; Tsuta, K.; Matsuno, Y.; Tateishi, U.; Yamamoto, S.; Nokihara, H.; Yamamoto, N.; Sekine, I.; Kunitoh, H.; Shibata, T.; Sakiyama, T.; Yoshida, T.; Tamura T. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 2005, 23, 6829-6837.
85. Hirsch, F. R.; Varella-Garcia, M.; McCoy, J.; West, H.; Xavier, A. C.; Gumerlock, P.; Bunn, P. A., Jr.; Franklin, W. A.; Crowley, J.; Gandara, D. R. Southwest Oncology Group. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J. Clin. Oncol. 2005, 23, 6838-6845.
86. Kearsley, J. H.; Leonard, J. H.; Walsh, M. D.; Wright, G. R. A comparison of epidermal growth factor receptor (EGFR) and c-erbB-2 oncogene expression in head and neck squamous cell carcinomas. Pathology 1991, 23, 189-194.
87. Rodrigo, J. P.; Ramos, S.; Lazo, P. S.; Alvarez, I.; Suarez, C. Amplification of ERBB oncogenes in squamous cell carcinomas of the head and neck. Eur. J. Cancer 1996, 32A, 2004-2010.
88. Werkmeister, R.; Brandt, B.; Joos, U. The erbB oncogenes as prognostic markers in oral squamous cell carcinomas. Am. J. Surg. 1996, 172, 681-683.
89. Werkmeister, R.; Brandt, B.; Joos, U. Clinical relevance of erbB-1 and -2 oncogenes in oral carcinomas. Oral Oncol. 2000, 36, 100-105.
90. O-charoenrat, P.; Rhys-Evans, P.; Eccles, S. Characterization of ten newly-derived human head and neck squamous carcinoma cell lines with special reference to c-erbB proto-oncogene expression. Anticancer Res. 2001, 21, 1953-1963.
91. Chung, C. H.; Ely, K.; McGavran, L.; Varella-Garcia, M.; Parker, J.; Parker, N.; Jarrett, C.; Carter, J.; Murphy, B. A.; Netterville, J.; Burkey, B. B.; Sinard, R.; Cmelak, A.; Levy, S.; Yarbrough, W. G.; Slebos, R. J.; Hirsch, F. R. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J. Clin. Oncol. 2006, 24, 4170-4176.
92. Amador, M. L.; Oppenheimer, D.; Perea, S.; Maitra, A.; Cusati, G.; Iacobuzio-Donahue, C.; Baker, S. D.; Ashfaq, R.; Takimoto, C.; Forastiere, A.; Hidalgo, M. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res. 2004, 64, 9139-9143.
93. Liu, W.; Innocenti, F.; Wu, M. H.; Desai, A. A.; Dolan, M. E.; Cook, E. H. Jr.; Ratain, M. J. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res. 2005, 65, 46-53.
94. Liu, W.; Innocenti, F.; Chen, P.; Das, S.; Cook, E. H., Jr.; Ratain, M. J. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin. Cancer Res. 2003, 9, 1009-1012.
95. Todd, R.; Donoff, B. R.; Gertz, R.; Chang, A. L.; Chow, P.; Matossian, K.; McBride, J.; Chiang, T.; Gallagher, G. T.; Wong, D. T. TGF-alpha and EGF-receptor mRNAs in human oral cancers. Carcinogenesis 1989, 10, 1553-1556.
96. Rubin-Grandis, J.; Tweardy, D. J. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993, 53, 3579-3584.
97. Thomson, S.; Buck, E.; Petti, F.; Griffin, G.; Brown, E.; Ramnarine, N.; Iwata, K. K.; Gibson, N.; Haley, J. D. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 2005, 65, 9455-9462.
98. Yauch, R. L.; Januario, T.; Eberhard, D. A.; Cavet, G.; Zhu, W.; Fu, L.; Pham, T. Q.; Soriano, R.; Stinson, J.; Seshagiri, S.; Modrusan, Z.; Lin, C. Y.; O'Neill, V.; Amler, L. C. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin. Cancer Res. 2005, 11, 8686-98.
99. Lorch, J. H.; Klessner, J.; Park, J. K.; Getsios, S.; Wu, Y. L.; Stack, M. S.; Green, K. J. Epidermal growth factor receptor inhibition promotes desmosome assembly and strengthens intercellular adhesion in squamous cell carcinoma cells. J. Biol. Chem. 2004, 279, 37191-200.